Takeda to sell OTC drug business to US private equity firm for $2.37B

Read the complete article here..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.

The drugmaker sustained debt when it got Shire, a U.K.-based drugmaker, in 2019, and the sale of its nonprescription drug division is planned to alleviate some of that debt..

More articles on drug store: FDA stops approval of blood plasma as COVID-19 treatmentJ&& J to obtain Momenta Pharma for $6.5 BUS sues Teva for alleged MS drug kickback scheme.

Japan-based Takeda Pharmaceutical will offer its non-prescription drug service to Blackstone Group, a U.S. private equity company, for $2.37 billion, according to the Nikkei Asian Review.

Takeda will focus its management resources on establishing prescription drugs, the business told the Nikkei Asian Review. It prepares to sell an overall of $10 billion in possessions..

Maia Anderson –
Wednesday, August 19th, 2020
Print|Email.